National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
Monash University, Melbourne, Australia.
JAMA Netw Open. 2021 Apr 1;4(4):e213059. doi: 10.1001/jamanetworkopen.2021.3059.
Despite concern about harms related to long-term prescribed opioid use among individuals with chronic noncancer pain (CNCP), no study has examined whether the same patients engage in a risky pattern of use consistently for the long term.
To examine the prevalence, incidence, persistence, and cessation of a range of opioid behaviors, indicators of extramedical use, and harm among individuals who are prescribed opioids.
DESIGN, SETTING, AND PARTICIPANTS: This 5-year prospective cohort study in communities across Australia included 1514 adults who were prescribed opioids for CNCP. Data collection took place from August 2012 to December 2018, and data analysis took place from February to November 2020.
Prescription opioid use.
High-dose opioid use (≥200 oral morphine equivalent [OME] mg/d); requesting an increase in opioid dose; requesting an early prescription renewal; tampering with opioid medication; diversion of medication to others; and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision opioid dependence. Cessation of opioid use was also assessed.
Of the 1514 participants, 672 (44.39%) were men, the mean (SD) age was 58 (19) years, and 737 (48.68%) were unemployed. At each annual interview, approximately 1 in 8 people (10.98% [95% CI, 10.33%-11.63%] to 14.73% [95% CI, 13.98%-15.48%] at any given interview) were taking more than 200 OME mg/d; comparatively more had requested an increased dosage in the previous 3 months (8.46% [95% CI, 7.89%-9.03%] to 23.77% [95% CI, 22.82%-24.73%]); and fewer asked for an early prescription renewal (4.61% [95% CI, 4.19%-5.03%] to 13.97% [95% CI, 13.24%-14.70%]). In any given interview, between 3.06% (95% CI, 2.72%-3.40%) and 7.86% (95% CI, 7.31%-8.41%) of respondents reported tampering and between 0.47% (95% CI, 0.33%-0.60%) and 1.39% (95% CI, 1.16%-1.62%) reported diversion to others. Between 8.28% (95% CI, 7.71%-8.84%) and 13.06% (95% CI, 12.35%-13.77%) met criteria for opioid dependence at each interview. Opioid cessation increased across interviews, from year 1 (9.15% [95% CI, 8.55%-9.74%]) to year 5 (20.02% [19.14%-20.89%]). There was considerable incidence and cessation in all behaviors from 1 interview to the next: most who engaged in any of these behaviors only did so at only 1 interview. For pharmaceutical opioid dependence, between 55.26% (95% CI, 53.81%-56.71%) and 64.44% (95% CI, 62.87%-66.00%) of cases in 1 interview did not meet dependence criteria in the following interview.
These findings suggest considerable fluidity in opioid use, extramedical behaviors, and opioid dependence among people with CNCP. This reinforces the need for reassessment of the effectiveness and safety of prescription opioid use over time.
尽管人们对慢性非癌性疼痛(CNCP)患者长期处方阿片类药物使用相关的危害感到担忧,但尚无研究表明同一患者是否会长期持续存在这种危险的用药模式。
评估长期处方阿片类药物的患者出现各种阿片类药物行为、非医疗用药指标和伤害的流行率、发生率、持续性和停药率。
设计、地点和参与者:这项在澳大利亚社区进行的为期 5 年的前瞻性队列研究纳入了 1514 名因 CNCP 而被处方阿片类药物的成年人。数据收集于 2012 年 8 月至 2018 年 12 月,数据分析于 2020 年 2 月至 11 月进行。
处方阿片类药物的使用。
高剂量阿片类药物使用(≥200 口服美沙酮等效剂量[OME]mg/d);要求增加阿片类药物剂量;要求提前处方续方;篡改阿片类药物;将药物转用于他人;以及国际疾病分类第十版阿片类药物依赖。还评估了阿片类药物的停药情况。
在 1514 名参与者中,672 名(44.39%)为男性,平均(SD)年龄为 58(19)岁,737 名(48.68%)失业。在每年的访谈中,大约每 8 人中就有 1 人(任何一次访谈时的 10.98%[95%CI,10.33%-11.63%]至 14.73%[95%CI,13.98%-15.48%])每天服用超过 200 OME mg/d;相比之下,更多人在过去 3 个月内要求增加剂量(8.46%[95%CI,7.89%-9.03%]至 23.77%[95%CI,22.82%-24.73%]);要求提前处方续方的人数较少(4.61%[95%CI,4.19%-5.03%]至 13.97%[95%CI,13.24%-14.70%])。在任何一次访谈中,3.06%(95%CI,2.72%-3.40%)至 7.86%(95%CI,7.31%-8.41%)的受访者报告篡改药物,0.47%(95%CI,0.33%-0.60%)至 1.39%(95%CI,1.16%-1.62%)的受访者报告将药物转用于他人。在每次访谈中,8.28%(95%CI,7.71%-8.84%)至 13.06%(95%CI,12.35%-13.77%)的受访者符合阿片类药物依赖的标准。阿片类药物的停药率在各次访谈中逐渐增加,从第 1 年(9.15%[95%CI,8.55%-9.74%])增加到第 5 年(20.02%[19.14%-20.89%])。从一次访谈到下一次访谈,所有行为都有相当大的发生率和停药率:大多数有这些行为的人只在一次访谈中发生。对于药物性阿片类药物依赖,在 1 次访谈中,55.26%(95%CI,53.81%-56.71%)至 64.44%(95%CI,62.87%-66.00%)的病例在下一次访谈中不符合依赖标准。
这些发现表明,慢性非癌性疼痛患者的阿片类药物使用、非医疗用药行为和阿片类药物依赖存在相当大的不稳定性。这再次强调了需要随着时间的推移重新评估处方阿片类药物使用的有效性和安全性。